Abstracts tagged "treatment and tyrosine kinase inhibition"

Abstract Number: 850 • 2014 ACR/ARHP Annual Meeting
Targeting Synovial Mast Cells in Spondyloarthritis: A Proof-of-Concept Study with the Tyrosine Kinase Inhibitor Nilotinib
Jacqueline E. Paramarta¹, Maureen C. Turina¹, Tanja F. Heijda², Iris C. Blijdorp³, Troy Noordenbos¹, Nataliya Yeremenko² and Dominique L. Baeten⁴, ¹Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Department of Clinical Immunology & Rheumatology, Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ⁴Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Immunopathological studies on synovitis recently identified the mast cell as potential novel therapeutic target in spondyloarthritis (SpA).[1] Mast cells can be targeted by inhibiting…
Abstract Number: 2566 • 2013 ACR/ARHP Annual Meeting
Nilotinib Treatment Effect In The Skin As Measured By DNA Microarray In Patients With Diffuse Systemic Sclerosis
Jessica K. Gordon¹, Tammara A. Wood², Robert F. Spiera¹ and Michael L. Whitfield², ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Gene expression profiling by DNA microarray is used to identify potential biomarkers in Systemic Sclerosis (SSc). Discrete gene expression signatures have been observed to…
Abstract Number: 709 • 2013 ACR/ARHP Annual Meeting
Nilotinib (Tasigna™) In The Treatment Of Early Diffuse Systemic Sclerosis: A Single Group, Open Label Pilot Clinical Trial – One Year Results
Jessica K. Gordon¹, Cynthia Magro², Uzunma Udeh¹, Daniele Lerner¹, Horatio F. Wildman³, Wei-Ti Huang⁴, Mary K. Crow⁵ and Robert F. Spiera¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Dermatopathology, Weill-Cornell Medical Center, New York, NY, ³Dermatology, Weill-Cornell Medical Center, New York, NY, ⁴Biostatistics, Hospital for Special Surgery, New York, NY, ⁵Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Tyrosine kinase inhibitors (TKI) are under investigation for the treatment of diffuse cutaneous Systemic Sclerosis (dcSSc.) Nilotinib is a second-generation TKI which selectively antagonizes c-abl and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].